SCNI vs MRNA
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 15, 2026
SCNI
MRNA
Investment Advisor Scores
MRNA
AI Analyst Insights
Detailed Metrics Comparison
| Metric | SCNI | MRNA | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 0 | 23.0415 | Tie |
| PEG Ratio | 0 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 146.0% | 2.1% | SCNI |
| Earnings Growth | 87.2% | -85.1% | SCNI |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 36.5/100 | 42.8/100 | MRNA |
| Profit Margin | -174.8% | -141.4% | MRNA |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | SELL | HOLD | MRNA |
Relative Price Performance (Last 90 Days)
Current Technical Phase
SCNI
MarkupPrice above SMA50, rising 50-day trend (230.5% over 20 days), RSI 67
MRNA
MarkupPrice above SMA50, rising 50-day trend (51.9% over 20 days), RSI 62
Fundamentals Snapshot
| Metric | SCNI | MRNA |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 0.0 | -30.6 |
| Trailing P/E | 0.1 | — |
| Revenue (TTM) | — | — |
| Revenue Growth | 1.5% | 0.0% |
| Gross Margin | -2.5% | -0.7% |
| Operating Margin | -4.7% | -5.6% |
| EPS | 28.07 | -7.98 |
| Dividend Yield | — | — |